Takeda Pharmaceutical (TAK) Capital Leases (2017 - 2019)

Takeda Pharmaceutical's Capital Leases history runs 3 years deep, the most recent figure standing at -$15.8 million for Q1 2019.

• On a quarterly basis, Capital Leases changed N/A year-over-year to -$15.8 million in Q1 2019; TTM through Mar 2019 was -$15.8 million, a N/A change from a year earlier, with the FY2019 full-year figure at -$15.8 million, changed N/A from the prior year.
• Capital Leases fell to -$15.8 million in Q1 2019 per TAK's latest filing, from -$14.2 million in the prior quarter.
• Across five years, Capital Leases topped out at -$14.2 million in Q4 2018 and bottomed at -$17.2 million in Q4 2017.
• The 3-year median for Capital Leases is -$15.8 million (2019), against an average of -$15.7 million.
• Biggest YoY gain for Capital Leases was 17.57% in 2018; the steepest drop was 17.57% in 2018.
• Year by year, Capital Leases stood at -$17.2 million in 2017, then gained by 17.57% to -$14.2 million in 2018, then decreased by 11.55% to -$15.8 million in 2019.
• Per Business Quant, the three latest TAK Capital Leases figures stand at -$15.8 million (Q1 2019), -$14.2 million (Q4 2018), and -$17.2 million (Q4 2017).